BR112023021133A2 - Receptores quiméricos de antígenos para direcionar cânceres positivos para cd5 - Google Patents

Receptores quiméricos de antígenos para direcionar cânceres positivos para cd5

Info

Publication number
BR112023021133A2
BR112023021133A2 BR112023021133A BR112023021133A BR112023021133A2 BR 112023021133 A2 BR112023021133 A2 BR 112023021133A2 BR 112023021133 A BR112023021133 A BR 112023021133A BR 112023021133 A BR112023021133 A BR 112023021133A BR 112023021133 A2 BR112023021133 A2 BR 112023021133A2
Authority
BR
Brazil
Prior art keywords
specific
chimeric antigen
targeting
positive cancers
antigen receptors
Prior art date
Application number
BR112023021133A
Other languages
English (en)
Inventor
Karen Nunez Cortes Ana
Marin Costa David
Elizabeth Shpall
Emily Ensley
Katy Rezvani
May Daher
Nadima Uprety
Rafet Basar
Sunil Acharya
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112023021133A2 publication Critical patent/BR112023021133A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

receptores quiméricos de antígenos para direcionar cânceres positivos para cd5. a presente invenção refere-se a métodos e composições relacionadas ao direcionamento de células que expressam cd5 com receptores específicos modificados. em modalidades específicas, as células nk são especificamente projetadas para se ligarem ao antígeno cd5 usando construtos específicas de receptor quimérico de antígeno. em certas modalidades, os vetores que expressam os cars direcionados a cd5 também expressam um gene suicida específico e/ou uma ou mais citocinas específicas.
BR112023021133A 2021-04-14 2022-04-14 Receptores quiméricos de antígenos para direcionar cânceres positivos para cd5 BR112023021133A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163174990P 2021-04-14 2021-04-14
PCT/US2022/024842 WO2022221548A1 (en) 2021-04-14 2022-04-14 Chimeric antigen receptors to target cd5-positive cancers

Publications (1)

Publication Number Publication Date
BR112023021133A2 true BR112023021133A2 (pt) 2023-12-12

Family

ID=83640731

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021133A BR112023021133A2 (pt) 2021-04-14 2022-04-14 Receptores quiméricos de antígenos para direcionar cânceres positivos para cd5

Country Status (9)

Country Link
EP (1) EP4322992A1 (pt)
JP (1) JP2024514203A (pt)
KR (1) KR20240007911A (pt)
CN (1) CN117480187A (pt)
AU (1) AU2022259658A1 (pt)
BR (1) BR112023021133A2 (pt)
CA (1) CA3216557A1 (pt)
IL (1) IL307408A (pt)
WO (1) WO2022221548A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023069969A1 (en) * 2021-10-20 2023-04-27 Board Of Regents, The University Of Texas System Engineering nk cells with a car construct with optimal signaling
WO2023070079A1 (en) * 2021-10-21 2023-04-27 Board Of Regents, The University Of Texas System Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160361360A1 (en) * 2015-06-12 2016-12-15 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
TW201908335A (zh) * 2017-07-25 2019-03-01 美國德州系統大學評議委員會 增強之嵌合抗原受體及其用途
US20230159618A1 (en) * 2017-07-25 2023-05-25 Board Of Regents, The University Of Texas System Enhanced chimeric antigen receptors and use thereof

Also Published As

Publication number Publication date
WO2022221548A1 (en) 2022-10-20
JP2024514203A (ja) 2024-03-28
KR20240007911A (ko) 2024-01-17
CA3216557A1 (en) 2022-10-20
IL307408A (en) 2023-12-01
EP4322992A1 (en) 2024-02-21
AU2022259658A1 (en) 2023-11-23
CN117480187A (zh) 2024-01-30

Similar Documents

Publication Publication Date Title
BR112023021133A2 (pt) Receptores quiméricos de antígenos para direcionar cânceres positivos para cd5
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
CL2019002717A1 (es) Receptores de unión a antígeno mejorados.
PH12020552138A1 (en) Bcma chimeric antigen receptors and uses thereof
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
PE20210256A1 (es) Anticuerpos anti-lag3
MX2020012445A (es) Receptores de antigeno quimericos con dominios enlazadores modificados y usos de los mismos.
BR112012010698A2 (pt) método para tratamento de um sujeito com câncer, método de triagem de uma célula de câncer de mama, e , anticorpo
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
BR112019006781A2 (pt) receptores de antígeno quiméricos para o tratamento de câncer
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
BR112021021843A2 (pt) Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas
BR112018001530A2 (pt) anticorpo biespecífico, polinucleotídeo, vetor, célula hospedeira, métodos para produzir o anticorpo biespecífico e de inibição do crescimento de células tumorais e composição farmacêutica
MX2013007392A (es) Anticuerpo modificado con vida media mejorada.
BR112021016984A2 (pt) Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
WO2020052692A3 (en) Binding molecules against cd3 and uses thereof
BRPI0812878C1 (pt) anticorpo isolado ou parte funcional do mesmo, vetor, método para produzir um anticorpo ou uma parte funcional do mesmo, para produzir uma célula produtora de anticorpo e para produzir um anticorpo capaz de se ligar especificamente a rsv, composição, e, uso de um anticorpo ou parte funcional do mesmo ou de uma composição ou de vetor
CL2019000119A1 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123.
PE20130207A1 (es) Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones
CR10652A (es) Anticuerpos monoclonales humanos especificos para light humano antagonistas
WO2015069922A3 (en) Alk antibodies, conjugates, and chimeric antigen receptors, and their use
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1
ZA202201464B (en) Anti-tigit antibodies and application thereof